Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation

Ho Sup Lee, Yang Soo Kim, Kihyun Kim, Jinseok Kim, Hyo Jung Kim, Chang Ki Min, Cheolwon Suh, Hyeon Seok Eom, Sung Soo Yoon, Jae Hoon Lee, Min Kyong Kim, Sung Hyun Kim, Sung Hwa Bae, Yeung Chul Mun, Deog Yeon Jo, Joo Seop Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation.

Original languageEnglish
Pages (from-to)80-86
Number of pages7
JournalJournal of Korean medical science
Volume28
Issue number1
DOIs
Publication statusPublished - 2013 Mar 13

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Drug Therapy
Survival
Disease-Free Survival
Bortezomib

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Ho Sup ; Kim, Yang Soo ; Kim, Kihyun ; Kim, Jinseok ; Kim, Hyo Jung ; Min, Chang Ki ; Suh, Cheolwon ; Eom, Hyeon Seok ; Yoon, Sung Soo ; Lee, Jae Hoon ; Kim, Min Kyong ; Kim, Sung Hyun ; Bae, Sung Hwa ; Mun, Yeung Chul ; Jo, Deog Yeon ; Chung, Joo Seop. / Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. In: Journal of Korean medical science. 2013 ; Vol. 28, No. 1. pp. 80-86.
@article{03433523178b413a82dd7bb630b853a6,
title = "Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation",
abstract = "Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6{\%} and 18.4{\%}, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3{\%} and 52.9{\%}, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation.",
author = "Lee, {Ho Sup} and Kim, {Yang Soo} and Kihyun Kim and Jinseok Kim and Kim, {Hyo Jung} and Min, {Chang Ki} and Cheolwon Suh and Eom, {Hyeon Seok} and Yoon, {Sung Soo} and Lee, {Jae Hoon} and Kim, {Min Kyong} and Kim, {Sung Hyun} and Bae, {Sung Hwa} and Mun, {Yeung Chul} and Jo, {Deog Yeon} and Chung, {Joo Seop}",
year = "2013",
month = "3",
day = "13",
doi = "10.3346/jkms.2013.28.1.80",
language = "English",
volume = "28",
pages = "80--86",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "1",

}

Lee, HS, Kim, YS, Kim, K, Kim, J, Kim, HJ, Min, CK, Suh, C, Eom, HS, Yoon, SS, Lee, JH, Kim, MK, Kim, SH, Bae, SH, Mun, YC, Jo, DY & Chung, JS 2013, 'Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation', Journal of Korean medical science, vol. 28, no. 1, pp. 80-86. https://doi.org/10.3346/jkms.2013.28.1.80

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. / Lee, Ho Sup; Kim, Yang Soo; Kim, Kihyun; Kim, Jinseok; Kim, Hyo Jung; Min, Chang Ki; Suh, Cheolwon; Eom, Hyeon Seok; Yoon, Sung Soo; Lee, Jae Hoon; Kim, Min Kyong; Kim, Sung Hyun; Bae, Sung Hwa; Mun, Yeung Chul; Jo, Deog Yeon; Chung, Joo Seop.

In: Journal of Korean medical science, Vol. 28, No. 1, 13.03.2013, p. 80-86.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation

AU - Lee, Ho Sup

AU - Kim, Yang Soo

AU - Kim, Kihyun

AU - Kim, Jinseok

AU - Kim, Hyo Jung

AU - Min, Chang Ki

AU - Suh, Cheolwon

AU - Eom, Hyeon Seok

AU - Yoon, Sung Soo

AU - Lee, Jae Hoon

AU - Kim, Min Kyong

AU - Kim, Sung Hyun

AU - Bae, Sung Hwa

AU - Mun, Yeung Chul

AU - Jo, Deog Yeon

AU - Chung, Joo Seop

PY - 2013/3/13

Y1 - 2013/3/13

N2 - Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation.

AB - Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84874778308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874778308&partnerID=8YFLogxK

U2 - 10.3346/jkms.2013.28.1.80

DO - 10.3346/jkms.2013.28.1.80

M3 - Article

VL - 28

SP - 80

EP - 86

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 1

ER -